People · Operator
Named in public records as an officer, director or promoter · active 2007–2021 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lux Biosciences Inc | — | Biotechnology | Series B | $81.1M | $635.0M | 2009 |
| PanOptica, Inc. | — | Biotechnology | Series C | $57.3M | $1.7B | 2010 |
| Allocure Inc | — | Biotechnology | Series B | $50.5M | $1.1B | 2009 |
| Logical Therapeutics Inc | — | Biotechnology | Series B | $42.5M | $396.9M | 2007 |
| Good Start Genetics, Inc. | — | Biotechnology | Series B | $28.2M | $396.9M | 2012 |
| IpiNovyx Bio, Inc. | — | Biotech / Pharma | Series A | $7.0M | $131.4M | 2021 |
Lutz Giebel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lutz Giebel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Guyer | 2 | 8 |
| Thomas Dyrberg | 2 | 5 |
| Carl Gordon | 1 | 24 |
| Gary Kurtzman | 1 | 8 |
| David Schnell | 1 | 7 |
| Mette Kirstine Agger | 1 | 6 |
| Axel Bolte | 1 | 6 |
| ABBIE CELNIKER | 1 | 6 |
| Bruce Peacock | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Bryant Fong | 1 | 5 |
| Martin Edwards | 1 | 5 |
| Paul Schmitt | 1 | 5 |
| Tracy Saxton | 1 | 5 |
| Robert Carpenter | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Marc Beer | 1 | 4 |
| Robert J. Carpenter | 1 | 3 |
| James Graham | 1 | 3 |
| Christof Westenfelder | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.